Psychiatric Drug Development: Digital Endpoint Solutions to Extract the Most Value from Your Clinical Study
Join our webinar to explore how digital endpoint solutions accelerate breakthroughs in psychiatric drug development. Learn how electronic clinical outcome assessments (eCOA), medical imaging, and cardiac safety monitoring enhance trial accuracy, improve patient experience, and drive innovation in psychiatric clinical trials. Discover the impact of cutting-edge technologies on advancing mental health treatments.
Click the register button for more details and sign up to explore how digital endpoint solutions like eCOA, medical imaging and cardiac safety monitoring are revolutionizing psychiatric drug development.
Session information:
By integrating advanced methodologies, researchers can overcome common challenges, improve data accuracy and enhance decision-making in psychiatric drug development. By attending this webinar, you will learn effective strategies to combat placebo responses and maximize trial success by implementing real-time data surveillance and developing tailored patient education programs to improve participant engagement and compliance.
Time:
- 11:00 a.m. – 12:00 p.m. ET (NA-East)
- 16:00 – 17:00 GMT (UK)
- 17:00 – 18:00 CET (EU-Central)
Moderator
Todd Rudo, M.D.
Chief Medical Officer at Clario
Dr. Todd Rudo is EVP and Chief Medical Officer at Clario, providing medical and scientific leadership across the organization. He has nearly 20 years of clinical cardiology and pharmaceutical research experience, with a career predominantly focused on drug safety. Dr. Rudo has board certifications in cardiology, cardiac electrophysiology, nuclear cardiology, adult echocardiography and internal medicine. His team provides expert consulting to clients on scientific and regulatory strategy, and ensures Clario’s product portfolio is scientifically robust, generating high quality clinical trial endpoint data. Dr. Rudo has a particular interest in applying innovative technologies to improve the scientific rigor of clinical trials, while maintaining focus on the customer experience, including minimizing patient and site burden.
Speakers
Prateek Verma, M.D.
Director, eCOA Science & Consulting at Clario
Dr. Prateek Verma is an M.D. with more than 20 years’ experience in clinical research. He has served as a Clinical Investigator in global neuro-psychiatry clinical trials. Dr. Verma has worked extensively in areas of AD, schizophrenia, MDD, bipolar, dementia, other behavioral disorders, infectious diseases and dermatology. Dr. Verma has also held advisory position for NIHR research design services and primary mental health clinical trials unit (PRIMENT) whilst working for Medical Research Council, UK, and University College London. He presently oversees eCOA design, investigator training and outcome analysis activities in global psychiatric, neurology and non-CNS indications and serves as an expert presenter at global investigator meetings and mentors scientific staff too.
Dave Scott, Ph.D.
Vice President, Medical & Scientific Affairs, Neuroscience at Clario
David Scott, Ph.D., is Vice President, Medical and Scientific Affairs at Clario. His aim is to facilitate drug development through standardized measurement of the neural correlates of neurodegenerative and other centrally mediated diseases. As a student at Johns Hopkins University and the University of Michigan, he employed multi-modal imaging approaches, including dynamic PET and functional MRI to study the neurobiology of placebo analgesia. At Omneuron, he developed real-time fMRI applications aimed at treating chronic pain, depression and addiction.
Alain Gay, M.D.
Senior Cardiologist, Cardiology at Clario
Dr. Alain Gay, MD, is board-certified in cardiology. After completing his training as a Cardiologist at the Hopital Cardiologique in Lille, France, Dr. Gay practiced for 10 years in a community hospital and completed his training in cardiac electrophysiology and cardiac pacing. Dr. Gay then moved into drug development and medical affairs studies for 15 years at Bayer. He contributed to establishing study standards in heart failure and contributed to the prelaunch and launch of both Xarelto®️ and Kerendia®️. At Clario, Dr. Gay is a contributor to the ECG core lab, also reading Holters and other recording devices. He works with our global customers to ensure their needs are met with robust, cost-effective solutions.